ORIC Posts $345M Cash Runway to 2028 as First Phase 3 Rinzimetostat Trial Begins
ORIC is trading near its 52-week low of $7.23 (4.0% above the low).
Summary
ORIC ended Q3 with $345.4 million in cash and investments, enough to fund operations into 2H 2028 and past the primary endpoint readout of its first Phase 3 trial. The company has started Himalayas-1, a ~600-patient global Phase 3 in post-abiraterone mCRPC, with Bayer supplying darolutamide at no cost while ORIC keeps full global rights to rinzimetostat. Updated durability data held up: landmark rPFS of 59% at 8, 9 and 10 months in the post-abiraterone cohort and 71%/59%/59% post-AR inhibitor, roughly in line with mevrometostat and well above the ~35-50% and ~15-50% ranges cited for approved therapies. The Q3 loss widened to $48.1 million from $32.6 million a year ago as R&D jumped to $43.4 million on rinzimetostat spending. Enozertinib's Redwood-1 Phase 3 in 1L EGFR atypical NSCLC is planned for 1H 2027, and CRUK will fully fund early development of ORIC-259. Stock sits near its 52-week low at $7.52, so execution on the Phase 3 starts is the swing factor.
At the time of this announcement, ORIC was trading at $7.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $779.5M. The 52-week trading range was $7.23 to $14.68. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.